Literature DB >> 15805342

Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction.

Eric T Moolchan1, Miqun L Robinson, Monique Ernst, Jean Lud Cadet, Wallace B Pickworth, Stephen J Heishman, Jennifer R Schroeder.   

Abstract

OBJECTIVES: To determine the safety and efficacy of the nicotine patch and gum for adolescents who want to quit smoking.
DESIGN: Double-blind, double-dummy, randomized, 3-arm trial with a nicotine patch (21 mg), nicotine gum (2 and 4 mg), or a placebo patch and gum; all participants received cognitive-behavioral group therapy.
SETTING: Inner-city, outpatient clinic on the East Coast. Subjects. Thirteen- to 17-year-old adolescents who smoked > or =10 cigarettes per day (CPD), scored > or =5 on the Fagerstrom Test of Nicotine Dependence, and were motivated to quit smoking. Intervention. Twelve weeks of nicotine patch or gum therapy with cognitive-behavioral therapy, with a follow-up visit at 6 months (3 months after the end of treatment). MAIN OUTCOME MEASURES: Safety assessed on the basis of adverse event reports for all 3 groups, prolonged abstinence, assessed through self-report and verified with exhaled carbon monoxide (CO) levels of < or =6 ppm, in intent-to-treat analyses, and smoking reduction (CPD and thiocyanate concentrations) among trial completers.
RESULTS: A total of 120 participants were randomized (72% white, 70% female; age: 15.2 +/- 1.33 years; smoking: 18.8 +/- 8.56 CPD; Fagerstrom Test of Nicotine Dependence score: 7.04 +/- 1.29) from 1999 to 2003. Participants started smoking at 11.2 +/- 1.98 years of age and had been smoking daily for 2.66 +/- 1.56 years; 75% had at least 1 current psychiatric diagnosis. Mean compliance across groups was higher for the patch (mean: 78.4-82.8%) than for the gum (mean: 38.5-50.7%). Both the patch and gum were well tolerated, and adverse events were similar to those reported in adult trials. Changes in mean saliva cotinine concentrations throughout treatment were not statistically significant. Intent-to-treat analyses of all randomized participants showed CO-confirmed prolonged abstinence rates of 18% for the active-patch group, 6.5% for the active-gum group, and 2.5% for the placebo group; the difference between the active-patch and placebo arms was statistically significant. There was no significant effect of patch versus gum or gum versus placebo on cessation outcomes. Abstinence rates at the 3-month follow-up assessment were sustained but were not significantly associated with treatment group. Mean smoking rates, but not CO or thiocyanate concentrations, decreased significantly in all 3 arms but not as a function of treatment group.
CONCLUSIONS: Nicotine patch therapy combined with cognitive-behavioral intervention was effective, compared with placebo, for treatment of tobacco dependence among adolescent smokers. Decreases in the numbers of cigarettes smoked appeared to be offset by compensatory smoking. Additional study of nicotine gum, with enhanced instructional support, is needed to assess its efficacy among adolescent smokers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15805342     DOI: 10.1542/peds.2004-1894

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  48 in total

1.  Pharmacotherapy for Substance Use Disorders in Youths.

Authors:  Christopher J Hammond; Kevin M Gray
Journal:  J Child Adolesc Subst Abuse       Date:  2016-04-20

2.  Association of post-treatment smoking change with future smoking and cessation efforts among adolescents with psychiatric comorbidity.

Authors:  Laura MacPherson; David R Strong; Christopher W Kahler; Ana M Abrantes; Susan E Ramsey; Richard A Brown
Journal:  Nicotine Tob Res       Date:  2007-12       Impact factor: 4.244

3.  Does allowing adolescents to smoke at home affect their consumption and dependence?

Authors:  Emily J Luther; Craig S Parzynski; Maria Jaszyna-Gasior; Kara S Bagot; Marc B Royo; Michelle K Leff; Eric T Moolchan
Journal:  Addict Behav       Date:  2008-01-26       Impact factor: 3.913

4.  Emerging Pharmacologic Treatments for Adolescent Substance Use: Challenges and New Directions.

Authors:  Robert Miranda; Hayley Treloar
Journal:  Curr Addict Rep       Date:  2016-04-02

5.  Cigarette smoking among HIV+ men and women: examining health, substance use, and psychosocial correlates across the smoking spectrum.

Authors:  Monica S Webb; Peter A Vanable; Michael P Carey; Donald C Blair
Journal:  J Behav Med       Date:  2007-06-15

6.  Gender differences in a randomized controlled trial treating tobacco use among adolescents and young adults with mental health concerns.

Authors:  Judith J Prochaska; Sebastien C Fromont; Danielle E Ramo; Kelly C Young-Wolff; Kevin Delucchi; Richard A Brown; Sharon M Hall
Journal:  Nicotine Tob Res       Date:  2015-04       Impact factor: 4.244

7.  Nicotine withdrawal produces a decrease in extracellular levels of dopamine in the nucleus accumbens that is lower in adolescent versus adult male rats.

Authors:  Luis A Natividad; Hugo A Tejeda; Oscar V Torres; Laura E O'Dell
Journal:  Synapse       Date:  2010-02       Impact factor: 2.562

8.  Effects of acute tobacco abstinence in adolescent smokers compared with nonsmokers.

Authors:  Anne E Smith; Dana A Cavallo; Tricia Dahl; Ran Wu; Tony P George; Suchitra Krishnan-Sarin
Journal:  J Adolesc Health       Date:  2008-03-06       Impact factor: 5.012

Review 9.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

10.  Puffing behavior during the smoking of a single cigarette in tobacco-dependent adolescents.

Authors:  Charles C Collins; David H Epstein; Craig S Parzynski; Debra Zimmerman; Eric T Moolchan; Stephen J Heishman
Journal:  Nicotine Tob Res       Date:  2009-12-07       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.